Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Dendreon Corporation

More Headlines »« Less Headlines

Dendreon () is a Seattle based biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.

Read More at Wikipedia ›

Related Topics

  1. Biotechnology
  2. CarMax
  3. Market Panel
  4. Eli Lilly
  5. News Corp.
  6. Progressive Corp.
Get updates on Dendreon Corporation
Dendreon Shares Drop On SEC Probe

Shares of Dendreon Corp.

slid 8% to $7.91 on Thursday following news that the Securities and Exchange Commission has launched a formal investigation into the biotech company. In a recent regulatory filing, Dendreon said that it believes the probe is related to certain shareholder suits and complaints that allege Dendreon misled investors about the commercial prospects of its lead product Provenge and the financial state of the company. Dendreon added that it was still unclear what financial impact, if any, the investigation and ongoing litigation might have on the company.Copyright © 2012 MarketWatch, Inc....

Read More ›

  1. Dendreon Soars 50% On Business Update

    Shares of biotech group Dendreon Corp. soared nearly 50% to $11.06 after it reported better-than-expected sales of its prostate cancer therapy Provenge. Dendreon att...

  2. Medivation Rockets 120% On Drug Study

    BOSTON -- Shares of Medivation Inc. rocketed 120% to $36.50 on Thursday after the biotech firm reported that a Phase III clinical study showed that its drug candidat...

  3. Measuring Pre-Earnings Upside in Biotechs (DNDN , HGSI, GILD, AMLN, ARIA, INCY, IBB, XBI, BBH)

    We have compiled a detailed list of expected upside in the biotech sector.  The sector has consolidated and now there is about to be a rush of earnings reports from ...

  4. Cancer Costs 'Becoming Unaffordable' in Rich Nations: Report

    An explosion of new technologies and treatments for cancer coupled with a rapid rise in cases of the disease worldwide mean cancer care is rapidly becoming unafforda...

  5. REFILE-UPDATE 1-Dendreon faces uphill battle to win credibility

    (Refiling to fix typographical error in 15th paragraph) BOSTON/NEW YORK (Reuters) - Dendreon Corp, which makes the high-priced prostate cancer vaccine Provenge, face...

  6. Dendreon Shares Tumble on Weak Vaccine Sales, Withdrawn Forecast

    Shares of Dendreon (NASDAQ:DNDN) plunged Thursday as investors digested its extremely disappointing earnings and dismal quarterly sales of cancer vaccine Provenge fr...

  7. Vulnerable Stocks From Soros Fund Liquidation

    George Soros is getting out of the hedge fund business.  Oddly enough, the regulatory climate under Dodd-Frank and other new regulations are the major reasons cited ...

  8. Vulnerable Stocks From Soros Fund Liquidation (ARX, BFLY, DNDN , EM, EXTR, HNR, IOC, MRCY, PLG, PWER, URS, VC, WPRT, AGRO)

    George Soros is getting out of the hedge fund business.  Oddly enough, the regulatory climate under Dodd-Frank and other new legislation are the major reasons cited ...

  9. Dendreon CEO on New Immunotherapy for Prostate Cancer

    Dendreon CEO Mitchell Gold on the biotech company’s advances in fighting prostate cancer.

  10. Quiet End to Tumultuous Quarter for Wall Street

    FOX Business: The Power to ProsperThe first quarter was a dizzying rollercoaster ride for the markets.  The Dow soared as much as 7% by February 18, gave back all of...

  11. Stocks Seesaw as Traders Eye Oil, Data

    FOX Business: The Power to ProsperThe markets bounced between positive and negative territory as traders mulled climbing oil prices and data pointing to continued re...

  12. Early-Market Movers: Dendreon , Rosetta Stone

    Stock futures were pointing to a lower opening on heightened U.S. and European debt concerns and following disappointing results from technology bellwether Cisco.Her...

  1. Dendreon Tumbles On Sales Report

    Shares of Dendreon Corp. tumbled 22% to $9.08 on Tuesday, the day after the biotech firm issued a weaker-than-expected earnings report. Analysts at Leerink Swann on ...

  2. Health Care Sector Wrap

    During trading today, the Health Care sector (XLV) showed little change while the S&P 500 fell 0.6%.The ETF is up 0.7% from its 50-day moving average and 5.4% from i...

  3. Is High U.S. Spending on Cancer Care 'Worth it'?

    With the United States spending more on healthcare than any other country - $2.5 trillion, or just over $8,000 per capita, in 2009 - the question has long been, is i...

  4. Dendreon Plunges 18% On Sales Report

    Shares of Dendreon Corp. plunged 18% to $12.12 on Monday after it issued a weaker-than-expected quarterly sales report for its prostate cancer therapy Provenge. Dend...

  5. Dendreon Names New CEO To Spur Sales Growth For Provenge

    Dendreon Corp. (DNDN) replaced its chief executive who steered the company on a difficult path toward regulatory approval of a new prostate-cancer therapy, only to f...

  6. Dendreon Picks Savient CEO Johnson To Succeed Gold At Helm

    DOW JONES NEWSWIRESDendreon Corp. (DNDN) picked John H. Johnson, the chief executive and president of Savient Pharmaceuticals Inc. (SVNT), to succeed longtime Presid...

  7. Dendreon Rallies For Second Day

    Shares of Dendreon Corp. shot up for the second day on Friday, climbing 11% to $11.73 after shooting up nearly 50% the previous session. On Thursday, Dendreon report...

‹ Prev12Next ›
Freebase CC-BY
Source: Dendreon Corporation on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL